Results 51 to 60 of about 49,034 (223)

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer

Annals of Oncology, 2016
The significant activity of poly(ADP-ribose)polymerase (PARP) inhibitors in the treatment of germline BRCA mutation-associated ovarian cancer, which represents ∼15% of HGS cases, has recently led to European Medicines Agency and food and drug administration approval of olaparib.
M, Moschetta, A, George, S B, Kaye, S, Banerjee   +3 more
openaire   +2 more sources

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

Advanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu, Zishu Wang, Lei Sun, Feng Qian   +12 more
wiley   +1 more source

Clinicopathological characteristics and BRCA1/BRCA2 pathogenic variants of patients with breast cancer

Polish Journal of Pathology
Although BRCA genes are well-known breast cancer genes, the clinicopathological features of breast cancer patients carrying BRCA1/2 pathogenic variants have not been adequately defined.
Nazan Eras, Ferah Tuncel, Zuhal Altıntas, Sema Erden   +3 more
doaj   +1 more source

A global perspective on the ethnic-specific BRCA variation and its implication in clinical application

Journal of the National Cancer Center, 2023
Pathogenic BRCA1 and BRCA2 (BRCA) variation is the genetic predisposition for high cancer risk affecting mostly breast and ovarian. BRCA variation information is widely used in clinical diagnosis, treatment, and prevention of BRCA-related cancer.
San Ming Wang
doaj   +1 more source

ITGB1 Regulates Triple‐Negative Breast Cancer Development by Modulating the Tumor Microenvironment

Advanced Science, EarlyView.
ABSTRACT Tumorigenesis and metastasis are frequently attributed to the intricate interplay between cancer cells and the tumor microenvironment (TME). Comprehending the mechanisms and key regulators of cancer‐immune crosstalk in the TME is imperative for developing efficacious immunotherapy.
Nuozi Song, Siqi Chen, Lei Wang, Jessica Dang, Xu Cao, Stephanie Singh, Lu Yang, Jinhui Wang, Steven T. Rosen, Yingyu Wang, Chun‐Wei D. Chen, Cheng Zhang, Mingye Feng   +12 more
wiley   +1 more source

Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials

Exploration of Targeted Anti-tumor Therapy
Tumors with an impaired ability to repair DNA double-strand breaks by homologous recombination, including those with alterations in breast cancer 1 and 2 (BRCA1 and BRCA2) genes, are very sensitive to blocking DNA single-strand repair by inhibition of ...
Martina Panebianco, Vittore Cereda, Mario Rosario D’Andrea   +2 more
doaj   +1 more source

BRCA Exchange Launches [PDF]

Cancer Discovery, 2019
Abstract The newly launched BRCA Exchange website and mobile app include data on more than 20,000 unique, inherited BRCA variants. Clinicians, researchers, and patients are expected to benefit from being able to access comprehensive, quality information on BRCA variants in a single place.
openaire   +1 more source

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto, Deborah Silverman, Tongxin Xie, Shamima Akhter, Nicole R. Vaughn, Adewale Adebayo, Kala Chand Debnath, Shorook Naara, Shajedul Islam, Erik Knutsen, Emily Lorin Ashkin, Simone Anfossi, Sara Leahey, Patrick Hwu, Sebastien Talbot, Erica K Sloan, Robert Saddawi‐Konefka, Roberto Rangel, Jeffrey N. Myers, George A. Calin, Moran Amit   +20 more
wiley   +1 more source

Multicohort Validation of Gut Microbiome Signatures for Cholangiocarcinoma Diagnosis and Functional Characterization of Bifidobacterium Pseudocatenulatum

Advanced Science, EarlyView.
This study analyzes gut bacteria in cholangiocarcinoma patients, revealing distinct microbial signatures that enable accurate disease detection. Species‐based diagnostic models achieved over 98% accuracy in identifying cholangiocarcinoma and distinguished it from other liver diseases. The research demonstrates that specific beneficial bacteria suppress
Benchen Rao, Jianwen Jiang, Ruiqing Zhang, Dongya Zhang, Chenchen Zhang, Ang Li, Haifeng Lu, Hua Zhang, Lin Zhou, Wenzhi Guo, Peihao Wen, Jianfeng Xue, Jie Pan, Tuerganaili Aji, Zhou Lan, Xianzhi Jiang, Shusen Zheng, Zujiang Yu, Zhigang Ren   +18 more
wiley   +1 more source

Practical aspects of treating relapsed BRCA-associated ovarian cancer

Медицинский совет, 2019
Ovarian cancer ranks first in the mortality causes pattern of female reproductive cancers in Russia. Treatment of relapsed ovarian cancer remains a significant challenge to practicing oncologists.
A. A. Rumyantse, A. S. Tyulyandina
doaj   +1 more source